Pacira Pharmaceuticals, Inc. Reports Its Phase 4 Study Of EXPAREL Achieved Primary Endpoint, Showed Statistically Significant Reductions In Opioid Consumption And Pain Scores In C-Section Patients
Benzinga Newsdesk